Department of Pharmacy, Shanghai Changhai Hospital, Naval Medical University, Shanghai, People's Republic of China; College of life sciences and Biopharmaceuticals, Shenyang Pharmaceutical University, Shenyang, People's Republic of China.
Department of Pharmacy, Shanghai Changhai Hospital, Naval Medical University, Shanghai, People's Republic of China; Department of Gastroenterology, Digestive Endoscopy Center, Changhai Hospital, Naval Medical University, Shanghai, People's Republic of China.
Transplant Rev (Orlando). 2024 Jul;38(3):100842. doi: 10.1016/j.trre.2024.100842. Epub 2024 Mar 21.
Tacrolimus (Tac) is commonly prescribed in solid organ transplantation to prevent immune-mediated damage to the graft. However, its pharmacokinetics show substantial variability between and within patients. Intra-patient variability of tacrolimus (Tac-IPV) has emerged as a novel marker to predict transplant outcomes. Numerous studies report varying associations between Tac-IPV and clinical outcomes, with Tac-IPV measures showing wide discrepancies among these studies. This inconsistency could be a significant factor that influences the various outcomes reported in different studies. Our review comprehensively assesses the relationship between various Tac-IPV measures and their associations with clinical outcomes in transplant patients.
A comprehensive literature search was conducted using the PubMed and Embase databases, covering the period from 2004 to March 31, 2023. The search focused on studies that examined the relationship between Tac-IPV and clinical outcomes in kidney transplantation (KT). The inclusion criteria were specific to studies addressing Tac-IPV, including measures such as standard deviation (SD), coefficient of variation (CV), time-weighted coefficient of variability (CV), mean absolute deviation (MAD), and Tac variability score (TVS). Clinical outcomes included the development of de novo donor-specific antibodies (dnDSA), rejection episodes, graft loss, and graft failure.
Among the 33 studies that met the inclusion criteria, a notable proportion presented conflicting findings in their assessment of various Tac-IPV measures regarding dnDSA, rejection episodes, graft loss, and graft failure.
Most studies have identified a correlation between high Tac-IPV and poor clinical outcomes; however, this relationship is multifactorial. Influencing factors include the metabolic status of KT patients, the timing of Tac-IPV calculations, and the criteria for defining high and low Tac-IPV thresholds, including the size and selection method. CV, MAD, and TWCV are the metrics that are most frequently used to determine Tac-IPV. Additionally, most of the methods for establishing Tac-IPV thresholds typically employ receiver operating characteristic (ROC) curves and median values. It is also notable that studies examining the clinical significance of Tac-IPV often include tacrolimus levels measured six months after kidney transplantation.
他克莫司(Tac)常用于实体器官移植中,以防止移植物发生免疫介导的损伤。然而,其药代动力学在患者之间和患者内部存在显著差异。患者内他克莫司变异性(Tac-IPV)已成为预测移植结局的新标志物。许多研究报告了 Tac-IPV 与临床结局之间的不同关联,并且这些研究中的 Tac-IPV 测量值存在很大差异。这种不一致性可能是影响不同研究报告的各种结局的一个重要因素。我们的综述全面评估了各种 Tac-IPV 测量值与移植患者临床结局之间的关系。
我们使用 PubMed 和 Embase 数据库进行了全面的文献检索,涵盖了 2004 年至 2023 年 3 月 31 日的时间段。搜索重点是研究 Tac-IPV 与肾移植(KT)患者临床结局之间关系的研究。纳入标准特定于研究 Tac-IPV 的研究,包括标准偏差(SD)、变异系数(CV)、时间加权变异系数(CV)、平均绝对偏差(MAD)和 Tac 变异评分(TVS)等措施。临床结局包括新出现的供体特异性抗体(dnDSA)的发展、排斥反应、移植物丢失和移植物衰竭。
在符合纳入标准的 33 项研究中,相当一部分研究在评估各种 Tac-IPV 测量值与 dnDSA、排斥反应、移植物丢失和移植物衰竭方面得出了相互矛盾的结论。
大多数研究已经确定了高 Tac-IPV 与不良临床结局之间存在相关性;然而,这种关系是多因素的。影响因素包括 KT 患者的代谢状态、Tac-IPV 计算的时间以及高 Tac-IPV 和低 Tac-IPV 阈值的定义标准,包括大小和选择方法。CV、MAD 和 TWCV 是最常用来确定 Tac-IPV 的指标。此外,建立 Tac-IPV 阈值的大多数方法通常采用接受者操作特征(ROC)曲线和中位数。值得注意的是,研究 Tac-IPV 临床意义的研究通常包括在肾移植后六个月测量的他克莫司水平。